These data are inconsistent with in vivo data in CKD animals demonstrating downregulation of DMP1 associated with osteocyte abnormalities, including impaired mineralization, that are improved with DMP1 administration and lower FGF23,41 possibly reflecting in vitro versus in vivo conditions. The gene discussed is FGF23; the disease is chronic kidney disease.